Back to search

Article

Neoadjuvant Chemotherapy in early-stage breast cancer: the trend over time and the impact on axillary management, A National Cancer Database Analysis

2025-07-14

Abstract excerpt

<title>Abstract</title> <p><bold>Background:</bold> Despite several benefits to neoadjuvant chemotherapy (NAC), there are uncertainties about NAC utilization in early breast cancer. <bold>Methods:</bold> We performed a retrospective analysis of the National Cancer Database (NCDB), selecting cN0, cT1-2, M0 breast cancers who received chemotherapy between 2010 and 2021. Axillary lymph node dissection candidacy (ALN...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
ba8a82c5-f720-5940-8aa6-de265e51f477
DOI
10.21203/rs.3.rs-6947236/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Neoadjuvant Chemotherapy in early-stage breast cancer: the trend over time and the impact on axillary management, A National Cancer Database AnalysisDOI 10.21203/rs.3.rs-6947236/v1
Comparison of the response to neoadjuvant therapy between immunohistochemistry HER2 (3+) and HER2 (2+)/ISH-positive early- stage breast cancer: A retrospective multicenter cohort studySemantic proximity
Long-term Results of the Expanded Application of the ACOSOG Z0011 Trial for Patients with Breast CancerSemantic proximity
Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-low and HER2-0 breast cancerSemantic proximity
Nomogram Based on Clinicopathologic and US Characteristics: Axillary Nodal Evaluation Following Neoadjuvant Chemotherapy in Patients with Biopsy-Proven Node-Positive Breast CancerSemantic proximity
Nomogram for predicting axillary lymph node pathological response in node-positive breast cancer patients after neoadjuvant chemotherapySemantic proximity
Somatic alterations of TP53, ERBB2, PIK3CA and CCND1 are associated with chemosensitivity for breast cancersSemantic proximity
Gene expression before and after neoadjuvant chemotherapy or endocrine therapy and survival outcomes in hormone receptor-positive, HER2-negative breast cancer: the NEOENDO studySemantic proximity
Estimated survival outcomes and absolute chemotherapy treatment benefit using PREDICT Tool® and EndoPredict®, in hormone-positive early-stage breast cancer.Semantic proximity
Adjuvant Chemotherapy Guidance for pT1-3N0-1 Breast Cancer Patients with HR+, HER2- subtype: a study based on SEER databaseSemantic proximity
Neoadjuvant carboplatin in triple-negative breast cancer: results from NACATRINE, a randomized phase II clinical trialSemantic proximity
Research on therapeutic clinical trials including immunotherapy in Triple- negative Breast cancer: A bibliometric analysisSemantic proximity
Mutational Status is Associated with a Higher Rate of Pathologic Complete Response After Neoadjuvant Chemotherapy in Hormone Receptor-Positive Breast Cancer.Semantic proximity
Select a neighboring publication to make it the new centre.